Insulin glargin v lechenii sakharnogo diabeta 2 tipa: dokazatel'naya otsenka ego klinicheskoy i ekonomicheskoy effektivnosti
https://doi.org/10.14341/2072-0351-5593
Abstract
References
1. IDF (International Diabetes Federation). Diabetes Atlas 3rd Edition (2006): Page 5
2. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. // Lancet 2005; 365(9467):1333-1346.
3. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.// Diabetes Care 2004; 27(5):1047-1053.
4. Roglic G, Unwin N, Bennett PH et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. // Diabetes Care 2005; 28:2130-2135.
5. Gray RP & Yudkin JS. Textbook of Diabetes 2nd Edition, 1997. Blackwell Sciences.
6. UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. //Diabetes Res 1990;13(1):1-11.
7. Skovlund S, Peyrot M on behalf of the DAWN International Advisory Panel. Results of the Cross-National Diabetes Attitudes, Wishes, and Needs (DAWN) Study // Diabetes Spectrum 2005; 18:136-142.
8. Koopmanschap M. Coping with type II diabetes: the patient's perspective. // Diabetologia 2002;45:S18-S22.
9. IDF (International Diabetes Federation). http://www.eatlas.idf.org/Costs_of_diabetes/Empirically_derived_cost_es timates. Last accessed 28/02/08 - Diabetes Atlas second edition - IDF.
10. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. //Arch Intern Med 1999;159:1873 1880.
11. Stratton IM, Adler AI, Neil AW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.// BMJ 2000;321: 405-412.
12. Nathan D, Buse JB, Davidson MB et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy // Diabetes Care 2006; 29(8):1963-1972.
13. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. // Diabetes Care. 2000;23:644-649.
14. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. // Diabetes. 2000; 49:2142-2148.
15. Luzio SD, Beck P, Owens DR. Comparison of the subcutaneous absorption of insulin glargine (Lantus®) and NPH insulin in patients with type 2 diabetes. // Horm Metab Res. 2003; 35:434-438.
16. Owens DR, Coates PA, Luzio SD, Tinbergen J P, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men. Comparison with NPH insulin and the influence of different subcutaneous injection sites. // Diabetes Care. 2000; 23:813-819.
17. Eliaschewitz FG, Calvo C, Valbuena H, et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. // Arch Med Res. 2006; 37:495-501.
18. Massi Benedetti MM, Humburg E, Dressler A, Ziemen M. A one-year, randomized, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. // Horm Metab Res. 2003; 35:189-196.
19. Pan C-Y, Sinnassamy P, Chung K-D, Kim K-W; LEAD Study Investigators Group. Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. // Diabetes Res Clin Pract. 2007; 76:111-118.
20. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study InvestigatorsThe treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. // Diabetes Care. 2003; 26:3080-3086.
21. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. // Diabetes Care. 2001; 24:631-636.
22. Yki-Jarvinen, Dressler A, Ziemen M; HOE 901/3002 Study Group. HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better postdinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. // Diabetes Care. 2000; 23:1130-1136.
23. Fritsche A, Schweitzer MA, H ring H-U; 4001 study group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized controlled trial. // Ann Intern Med. 2003; 138:952-959.
24. Schreiber SA, Haak T. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. // Diabetes Obes Metab. 2007;9:31-38.
25. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. // Diabetes Care. 2005; 28:950-955.
26. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; AT.LANTUS study group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. // Diabetes Care. 2005; 28:1282-1288.
27. Kennedy L, Herman WH, Strange P, Harris A; GOAL A1C Team. Impact of active versus usual algorithmic titration of basal insulin and point-ofcare versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. // Diabetes Care. 2006; 29:1-8.
28. Chakkarwar PN, Manjrekar NA. Insulin glargine: a long acting insulin analog.// J Postgrad Med. 2005; 51:68-71.
29. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. // Diabetologia. 2006;49:442-451.
30. Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a mulitcenter, randomized, parallel group study.// Am J Med Sci. 2004; 328:274-280.
31. Rosenstock J, Davies M, Home PD et al. A randomized, 52-week, treatto- target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-na ve people with type 2 diabetes. // Diabetologia 2008; 51:408-416.
32. Currie CJ, Poole CD, Tetlow T, Holmes P, McEwan P. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis.// Curr Med Res Opin. 2007; 23(Suppl. 1):S33-S39.
33. Gerstein HC, Yale J-F, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hypoglycaemia Treatment) study. // Diabet Med. 2006; 23:736-742.
34. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki- J rvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. // Diabetes Care. 2005;28:254-259.
35. Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. // J Am Geriatr Soc. 2007; 55:182-188.
36. Raskin P, Allen E, Hollander P, et al; INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. // Diabetes Care. 2005; 28:260-265.
37. Raskin PR, Hollander PA, Lewin A, Gabbay RA, Bode B, Garber AJ; INITIATE Study Group. Basal insulin or premix analogue therapy in type 2 diabetes patients. // Eur J Intern Med. 2007;18:56-62.
38. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; Lispro Mixture-Glargine study group. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. // Clin Ther. 2004; 26:2034-2044.
39. Bradley C, Plewe G, Kliebe-Frisch C et al. // Diabetes 2005;54(suppl 1):A304. Abstract 1246P.
40. Davies M. // Value Health 2005; 8(6):A174, Abstract PDB62.
41. Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. // Curr Med Res Opin. 2004; 20:1703-1710.
42. Dixon S, Peters JR. Evaluating the 'real' cost-effectiveness of health technology: reconciling the public interest with patients' interests. // Curr Med Res Opin. 2007; 23(Suppl. 1):S1-S6.
43. Yki-Jarvinen H, Juurinen L, Alvarsson M et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. // Diabetes Care 2007;30:1364- 1369.
44. Davies M, Evans R, Storms F et al. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. // Diab Obes Metab 2007; 9:706-713.
45. Bullano MF, Fisher MD, Grochulski WD, Menditto L, Willey VJ. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. //Am J Health Syst Pharm. 2006; 63:2473-2482.
46. McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. // Curr Med Res Opin. 2007b; 23 (Suppl. 1):S21-S31.
47. Poole CD, Tetlow T, McEwan P, Holmes P, Currie CJ. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. // Curr Med Res Opin. 2007; 23(Suppl. 1):S41-S48.
48. Janka H.U., Hogy B. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial/ Eur J Health Econ/ DOI 10.1007/s10198-007-0057-2
49. Miller D.R., Gardner J.A., Hendricks A.M. et al. Health Care Resource Utilization and Expenditures Associated with the Use of Insulin Glargine. Clin. Ther 2007; 29 (3):478-87.
50. Skyler JS. Effects of glycemic control on diabetes complications and on the prevention of diabetes. // Clin Diabetes. 2004; 22:162-166.
51. Milicevic Z, Raz I, Strojek K, et al; HEART2D Study. Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with type 2 diabetes mellitus (HEART2D) study design. // J Diabetes Complications. 2005;19:80-87.
Review
For citations:
Glinkina I.V. Insulin glargin v lechenii sakharnogo diabeta 2 tipa: dokazatel'naya otsenka ego klinicheskoy i ekonomicheskoy effektivnosti. Diabetes mellitus. 2008;11(4):60-65. https://doi.org/10.14341/2072-0351-5593
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
